CRC Research Update — July 15, 2026
Today's colorectal cancer research highlights
braf
A collection of 55 issues
CRC Research Update — July 13, 2026
Today's colorectal cancer research highlights
Furin Inhibition Targets KRAS and BRAF Pathways
Skip to content
The CRC Digest
Furin Inhibition Targets KRAS and BRAF Pathways
Blocking Furin improved chemotherapy sensitivity in KRAS- and BRAF-mutant organoids. (Oncogene)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026 The CRC Digest —
crcdigest.com
CRC Research Finding
Skip to content
The CRC Digest
◇ Furin Protein Sustains Tumor Signals in KRAS- and BRAF-Mutated Colorectal Cancer
Preclinical research identifies Furin as a key mediator of the TGF-β1-COX-2 pathway in KRAS- and BRAF-mutant colorectal cancer; blocking Furin suppressed tumor growth and enhanced sensitivity to chemotherapy in organoid models. (Oncogene)
This
CRC Research Update — July 12, 2026
Today's colorectal cancer research highlights
This Week in CRC Research — July 12, 2026
Weekly colorectal cancer research intelligence
Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer
Skip to content
The CRC Digest
▸ TREATMENT
Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer — Clinical Colorectal Cancer
A case report from the AGMT mCRC Registry documented successful encorafenib and cetuximab re-challenge combined with nivolumab in BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer.
If you have BRAF
KRAS, NRAS, and BRAF mutation patterns in Chile
Skip to content
The CRC Digest
KRAS, NRAS, and BRAF mutation patterns in Chile
Real-world data from 999 Chilean patients characterized the frequency and sex-specific distribution of KRAS, NRAS, and BRAF mutations. (Journal of Gastrointestinal Oncology)
This content is informational only and does not constitute medical advice.
Always consult your
RAS and BRAF status in MSI-H/dMMR metastatic CRC
Skip to content
The CRC Digest
RAS and BRAF status in MSI-H/dMMR metastatic CRC
New guidance on the role of RAS and BRAF mutations in MSI-high and dMMR metastatic colorectal cancer. (Oncodaily)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care
CRC Research Update — July 06, 2026
Today's colorectal cancer research highlights